Dimerix Advances FSGS Trial with Strategic Partnerships

Dimerix Limited (AU:DXB) has released an update.

Dimerix Limited has partnered with the UK’s RaDaR to improve patient recruitment in the UK for its ACTION3 Phase 3 clinical trial targeting FSGS, a rare kidney disease. The collaboration is expected to boost enrollment rates by leveraging RaDaR’s extensive registry of over 34,500 patients. Meanwhile, Dimerix has also received Thai FDA approval for its IND, with patient recruitment in Thailand to commence shortly.

For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.